Claims for Patent: 12,268,696

Summary for Patent: 12,268,696

Title:	Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
Abstract:	The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
Inventor(s):	Joseph HULIHAN, Alex Aimetti, Scott BRAUNSTEIN
Assignee:	Marinus Pharmaceuticals Inc
Application Number:	US18/905,502
Patent Claims:	1. A method for treating seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, comprising orally administering to a subject in need thereof ganaxolone in an amount of: about 150 mg per day for about one week, followed by about 300 mg per day for about one week, followed by about 600 mg per day for about one week, followed by about 1,200 mg per day for about one week, followed by about up to 1,800 mg per day for the remaining treatment period. 2. The method of claim 1, wherein the subject is concomitantly being administered cannabidiol. 3. The method of claim 1, wherein about 50 mg are administered three times a day for about one week, followed by about 100 mg administered three times a day for about one week, followed by about 200 mg administered three times a day for about one week, followed by about 400 mg administered three times a day for about one week, followed by 600 mg administered three times a day for the remaining treatment period. 4. The method of claim 1, wherein ganaxolone is administered as an oral suspension or oral solution. 5. The method of claim 1, wherein ganaxolone is administered as an oral capsule or tablet. 6. The method of claim 1, wherein the treatment period is for at least about 5 weeks or longer. 7. The method of claim 1, wherein administration of ganaxolone does not result in somnolence in the subject. 8. The method of claim 1, wherein administering ganaxolone reduces the frequency of seizure in the subject relative to baseline. 9. The method of claim 1, wherein administering ganaxolone results in a reduction in seizure frequency of about 20% or greater relative to baseline seizure frequency. 10. A method for treating seizures associated with CDKL5 deficiency disorder, comprising orally administering to a subject in need thereof ganaxolone in an amount of: about 6 mg/kg/day for about one week, followed by about 12 mg/kg/day for about one week, followed by about 24 mg/kg/day for about one week, followed by about 42 mg/kg/day for about one week, followed by about up to 63 mg/kg/day for the remaining treatment period. 11. The method of claim 10, wherein about 2 mg/kg are administered three times a day for about one week, followed by about 4 mg/kg administered three times a day for about one week, followed by about 8 mg/kg administered three times a day for about one week, followed by about 14 mg/kg administered three times a day for about one week, followed by 21 mg/kg administered three times a day for the remaining treatment period. 12. The method of claim 10, wherein ganaxolone is administered as an oral suspension or oral solution. 13. The method of claim 10, wherein ganaxolone is administered as an oral capsule or tablet. 14. The method of claim 10, wherein the treatment period is for at least about 5 weeks or longer. 15. The method of claim 10, wherein administration of ganaxolone does not result in somnolence in the subject. 16. The method of claim 10, wherein administering ganaxolone reduces the frequency of seizure in the subject relative to baseline. 17. The method of claim 10, wherein administering ganaxolone results in a reduction in seizure frequency of about 20% or greater relative to baseline seizure frequency. 18. The method of claim 1, wherein the subject weighs more than 28 kg. 19. The method of claim 3, wherein the subject weighs more than 28 kg. 20. The method of claim 10, wherein the subject weighs 28 kg or less. 21. The method of claim 11, wherein the subject weighs 28 kg or less. 22. The method of claim 10, wherein the subject is concomitantly being administered cannabidiol.